Literature DB >> 7600189

Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria.

R L Doty1, S M Bromley, M B Stern.   

Abstract

Since olfactory dysfunction is among the first signs of idiopathic Parkinson's disease (PD), olfactory testing may aid in the early of 'preclinical' diagnosis of this disorder. Indeed, the proportion of early-stage PD patients with olfactory dysfunction appears to be greater than the proportion of early-stage PD patients exhibiting some of the cardinal signs of PD. Because olfactory function varies in the general population and declines with age, empirically-based criteria are needed by the clinician to establish whether the degree of olfactory loss observed in a given patient is concordant with the presence of PD. In this study, we present cutoff criteria for the optimal assessment of olfactory dysfunction in the evaluation of PD. Specifically, we present scores for the University of Pennsylvania Smell Identification Test (UPSIT) that best discriminate between PD patients and age-matched controls. Receiver operating characteristic (ROC) curves, based upon sensitivity and specificity estimates, were computed for three age groups (< or = 60 yrs, 61-70 yrs, and > or = 71 yrs) and scores with highest sensitivity and specificity were determined. Sex- and age-related differences in the test scores were observed, with lower scores occurring for men and for the older patient groups.

Entities:  

Mesh:

Year:  1995        PMID: 7600189     DOI: 10.1006/neur.1995.0011

Source DB:  PubMed          Journal:  Neurodegeneration        ISSN: 1055-8330


  47 in total

1.  An impairment in sniffing contributes to the olfactory impairment in Parkinson's disease.

Authors:  N Sobel; M E Thomason; I Stappen; C M Tanner; J W Tetrud; J M Bower; E V Sullivan; J D Gabrieli
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

Review 2.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

Review 3.  Olfactory dysfunction and its measurement in the clinic and workplace.

Authors:  Richard L Doty
Journal:  Int Arch Occup Environ Health       Date:  2006-01-21       Impact factor: 3.015

4.  Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease.

Authors:  Tyler M Rolheiser; Heather G Fulton; Kimberley P Good; John D Fisk; J Roger McKelvey; Christophe Scherfler; Naeem M Khan; Ronald A Leslie; Harold A Robertson
Journal:  J Neurol       Date:  2011-02-03       Impact factor: 4.849

5.  Impact of limiting visual input on gait: Individuals with Parkinson disease, age-matched controls, and healthy young participants.

Authors:  Laura M Pilgram; Gammon M Earhart; Kristen A Pickett
Journal:  Somatosens Mot Res       Date:  2016-03-18       Impact factor: 1.111

Review 6.  Preclinical diagnosis of Parkinson's disease: are we there yet?

Authors:  Andrew Siderowf; Matthew B Stern
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

7.  Olfactory function in young adolescents with Down's syndrome.

Authors:  D A McKeown; R L Doty; D P Perl; R E Frye; I Simms; A Mester
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

8.  Cognitive function and other non-motor features in non-demented Parkinson's disease motor subtypes.

Authors:  Talia Herman; Aner Weiss; Marina Brozgol; Adi Wilf-Yarkoni; Nir Giladi; Jeffrey M Hausdorff
Journal:  J Neural Transm (Vienna)       Date:  2014-12-10       Impact factor: 3.575

9.  Olfactory FMRI in patients with Parkinson's disease.

Authors:  Thomas Hummel; Klaus Fliessbach; Michael Abele; Thorsten Okulla; Jens Reden; Heinz Reichmann; Ullrich Wüllner; Antje Haehner
Journal:  Front Integr Neurosci       Date:  2010-10-28

10.  Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Argelia Esperanza Rojas-Mayorquin; Claudia P Figueiredo; Filipe C Matheus; Laure Ginestet; Caroline Chevarin; Elaine Del Bel; Raymond Mongeau; Michel Hamon; Laurence Lanfumey; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2009-07-21       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.